Therapeutic of Mesenchymal Stem Cells in Diabetes

Deby Susanti Vinski; Natasha  Cinta Vinski Borneo

doi:10.58344/jws.v2i11.497

Authors

Deby Susanti Vinski Celltech Stem Cell Laboratory & Banking, Jakarta, Indonesia
Natasha Cinta Vinski Borneo Celltech Stem Cell Laboratory & Banking, Jakarta, Indonesia

DOI:

https://doi.org/10.58344/jws.v2i11.497

Keywords:

therapeutic, diabetes, mcs

Abstract

This study aims to explain and analyze the effective treatment of diabetes mellitus by Mesenchymal Stem Cells with respect to traditional therapy based on oral anti-diabetic drugs. As well as to study its regularly consistent properties. The method used in this research is the case study method. Patient care records were the main source of data for this study including evaluation and analysis. So that the results of the study explain that at the same time the utilized products cultured by "CELLTECH STEM CELL LAB. and BANKING" as an integrated part of the Clinic, also get quality assurance. Effectiveness and efficiency including endogenous beta cell regeneration of pancreatic islets, and other therapeutic issues are novel and belong to cutting-edge treatment. Treatments performed at the Vinski Regenerative Stem Cell Main Clinic have shown positive research results. This has strengthened the level of trust in the clinic's medical services.

References

Ammar, H. I., Sequiera, G. L., Nashed, M. B., Ammar, R. I., Gabr, H. M., Elsayed, H. E., Sareen, N., Rub, E. A.-E., Zickri, M. B., & Dhingra, S. (2015). Comparison of adipose tissue-and bone marrow-derived mesenchymal stem cells for alleviating doxorubicin-induced cardiac dysfunction in diabetic rats. Stem Cell Research & Therapy, 6(1), 1–14.

Anstee, Q. M., Targher, G., & Day, C. P. (2013). Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nature Reviews Gastroenterology & Hepatology, 10(6), 330–344.

Bagley, R. G., Weber, W., Rouleau, C., Yao, M., Honma, N., Kataoka, S., Ishida, I., Roberts, B. L., & Teicher, B. A. (2009). Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers. International Journal of Oncology, 34(3), 619–627.

Baranovskii, D. S., Klabukov, I. D., Arguchinskaya, N. V, Yakimova, A. O., Kisel, A. A., Yatsenko, E. M., Ivanov, S. A., Shegay, P. V, & Kaprin, A. D. (2022). Adverse events, side effects and complications in mesenchymal stromal cell-based therapies. Stem Cell Investigation, 9.

Bhansali, A., Asokumar, P., Walia, R., Bhansali, S., Gupta, V., Jain, A., Sachdeva, N., Sharma, R. R., Marwaha, N., & Khandelwal, N. (2014). Efficacy and safety of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus: a randomized placebo-controlled study. Cell Transplantation, 23(9), 1075–1085.

Bhansali, A., Upreti, V., Khandelwal, N., Marwaha, N., Gupta, V., Sachdeva, N., Sharma, R. R., Saluja, K., Dutta, P., & Walia, R. (2009). Efficacy of autologous bone marrow–derived stem cell transplantation in patients with type 2 diabetes mellitus. Stem Cells and Development, 18(10), 1407–1416.

Bhansali, S., Dutta, P., Kumar, V., Yadav, M. K., Jain, A., Mudaliar, S., Bhansali, S., Sharma, R. R., Jha, V., & Marwaha, N. (2017). Efficacy of autologous bone marrow-derived mesenchymal stem cell and mononuclear cell transplantation in type 2 diabetes mellitus: a randomized, placebo-controlled comparative study. Stem Cells and Development, 26(7), 471–481.

Bi, S., Nie, Q., Wang, W., Zhu, Y., Ma, X., Wang, C., Zhang, B., Li, H., Zhang, Q., & Chen, G. (2018). Human umbilical cord mesenchymal stem cells therapy for insulin resistance: a novel strategy in clinical implication. Current Stem Cell Research & Therapy, 13(8), 658–664.

Borg, D. J., Weigelt, M., Wilhelm, C., Gerlach, M., Bickle, M., Speier, S., Bonifacio, E., & Hommel, A. (2014). Mesenchymal stromal cells improve transplanted islet survival and islet function in a syngeneic mouse model. Diabetologia, 57, 522–531.

Boumaza, I., Srinivasan, S., Witt, W. T., Feghali-Bostwick, C., Dai, Y., Garcia-Ocana, A., & Feili-Hariri, M. (2009). Autologous bone marrow-derived rat mesenchymal stem cells promote PDX-1 and insulin expression in the islets, alter T cell cytokine pattern and preserve regulatory T cells in the periphery and induce sustained normoglycemia. Journal of Autoimmunity, 32(1), 33–42.

Caplan, A. I., & Dennis, J. E. (2006). Mesenchymal stem cells as trophic mediators. Journal of Cellular Biochemistry, 98(5), 1076–1084.

Chandravanshi, B., & Bhonde, R. R. (2017). Shielding engineered islets with mesenchymal stem cells enhance survival under hypoxia. Journal of Cellular Biochemistry, 118(9), 2672–2683.

Chen, J., Zheng, C.-X., Jin, Y., & Hu, C.-H. (2021). Mesenchymal stromal cell-mediated immune regulation: a promising remedy in the therapy of type 2 diabetes mellitus. Stem Cells, 39(7), 838–852.

Chen, L.-B., Jiang, X.-B., & Yang, L. (2004). Differentiation of rat marrow mesenchymal stem cells into pancreatic islet beta-cells. World Journal of Gastroenterology: WJG, 10(20), 3016.

Cho, J., D’Antuono, M., Glicksman, M., Wang, J., & Jonklaas, J. (2018). A review of clinical trials: mesenchymal stem cell transplant therapy in type 1 and type 2 diabetes mellitus. American Journal of Stem Cells, 7(4), 82.

Cosenza, S., Toupet, K., Maumus, M., Luz-Crawford, P., Blanc-Brude, O., Jorgensen, C., & Noël, D. (2018). Mesenchymal stem cells-derived exosomes are more immunosuppressive than microparticles in inflammatory arthritis. Theranostics, 8(5), 1399.

Dang, L. T.-T., Bui, A. N.-T., Pham, V. M., Phan, N. K., & Van Pham, P. (2015). Production of islet-like insulin-producing cell clusters in vitro from adiposederived stem cells. Biomedical Research and Therapy, 2, 1–9.

Dang, L. T.-T., Phan, N. K., & Truong, K. D. (2017). Mesenchymal stem cells for diabetes mellitus treatment: new advances. Biomedical Research and Therapy, 4(1), 1062–1081.

de Witte, S. F. H., Luk, F., Sierra Parraga, J. M., Gargesha, M., Merino, A., Korevaar, S. S., Shankar, A. S., O’Flynn, L., Elliman, S. J., & Roy, D. (2018). Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells. Stem Cells, 36(4), 602–615.

Deng, Z., Xu, H., Zhang, J., Yang, C., Jin, L., Liu, J., Song, H., Chen, G., Han, W., & Si, Y. (2018). Infusion of adipose?derived mesenchymal stem cells inhibits skeletal muscle mitsugumin 53 elevation and thereby alleviates insulin resistance in type 2 diabetic rats. Molecular Medicine Reports, 17(6), 8466–8474.

Ding, Y., Liang, X., Zhang, Y., Yi, L., Shum, H. C., Chen, Q., Chan, B. P., Fan, H., Liu, Z., & Tergaonkar, V. (2018). Rap1 deficiency-provoked paracrine dysfunction impairs immunosuppressive potency of mesenchymal stem cells in allograft rejection of heart transplantation. Cell Death & Disease, 9(3), 386.

Domínguez-Bendala, J., Lanzoni, G., Inverardi, L., & Ricordi, C. (2012). Concise review: mesenchymal stem cells for diabetes. Stem Cells Translational Medicine, 1(1), 59–63.

El-Badawy, A., & El-Badri, N. (2016). Clinical efficacy of stem cell therapy for diabetes mellitus: a meta-analysis. PloS One, 11(4), e0151938.

El-Sherbiny, M., Eladl, M. A., Ranade, A. V., Guimei, M., & Gabr, H. (2020). Functional beta-cells derived from umbilical cord blood mesenchymal stem cells for curing rats with streptozotocin-induced diabetes mellitus. Singapore Medical Journal, 61(1), 39.

Esser, N., Legrand-Poels, S., Piette, J., Scheen, A. J., & Paquot, N. (2014). Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Research and Clinical Practice, 105(2), 141–150.

Esteves, J., Laranjeira, A. F., Roggia, M. F., Dalpizol, M., Scocco, C., Kramer, C. K., Azevedo, M. J., & Canani, L. H. (2008). Fatores de risco para retinopatia diabética. Arquivos Brasileiros de Endocrinologia & Metabologia, 52, 431–441.

Estrada, E. J., Valacchi, F., Nicora, E., Brieva, S., Esteve, C., Echevarria, L., Froud, T., Bernetti, K., Cayetano, S. M., & Velazquez, O. (2008). Combined treatment of intrapancreatic autologous bone marrow stem cells and hyperbaric oxygen in type 2 diabetes mellitus. Cell Transplantation, 17(12), 1295–1304.

Ezquer, M., Ezquer, F., Ricca, M., Allers, C., & Conget, P. (2011). Intravenous administration of multipotent stromal cells prevents the onset of non-alcoholic steatohepatitis in obese mice with metabolic syndrome. Journal of Hepatology, 55(5), 1112–1120.

Gabr, M. M., Zakaria, M. M., Refaie, A. F., Ismail, A. M., Abou-El-Mahasen, M. A., Ashamallah, S. A., Khater, S. M., El-Halawani, S. M., Ibrahim, R. Y., & Uin, G. S. (2013). Insulin-producing cells from adult human bone marrow mesenchymal stem cells control streptozotocin-induced diabetes in nude mice. Cell Transplantation, 22(1), 133–145.

Galie, M., Konstantinidou, G., Peroni, D., Scambi, I., Marchini, C., Lisi, V., Krampera, M., Magnani, P., Merigo, F., & Montani, M. (2008). Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice. Oncogene, 27(18), 2542–2551.

Gao, F., Chiu, S. M., Motan, D. A. L., Zhang, Z., Chen, L., Ji, H. L., Tse, H. F., Fu, Q.-L., & Lian, Q. (2016). Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death & Disease, 7(1), e2062–e2062.

Gao, S., Zhang, Y., Liang, K., Bi, R., & Du, Y. (2022). Mesenchymal stem cells (MSCs): a novel therapy for type 2 diabetes. Stem Cells International, 2022.

Garofalo, C., Iazzetta, N., Camocardi, A., Pacilio, M., Iodice, C., Minutolo, R., De Nicola, L., & Conte, G. (2015). Anti-diabetics and chronic kidney disease. Giornale Italiano Di Nefrologia: Organo Ufficiale Della Societa Italiana Di Nefrologia, 32(5).

Ghoneim, M. A., Refaie, A. F., Elbassiouny, B. L., Gabr, M. M., & Zakaria, M. M. (2020). From mesenchymal stromal/stem cells to insulin-producing cells: progress and challenges. Stem Cell Reviews and Reports, 16, 1156–1172.

Gomzikova, M. O., James, V., & Rizvanov, A. A. (2021). Mitochondria donation by mesenchymal stem cells: current understanding and mitochondria transplantation strategies. Frontiers in Cell and Developmental Biology, 9, 653322.

Hao, H., Liu, J., Shen, J., Zhao, Y., Liu, H., Hou, Q., Tong, C., Ti, D., Dong, L., & Cheng, Y. (2013). Multiple intravenous infusions of bone marrow mesenchymal stem cells reverse hyperglycemia in experimental type 2 diabetes rats. Biochemical and Biophysical Research Communications, 436(3), 418–423.

Hashemian, S. J., Kouhnavard, M., & Nasli-Esfahani, E. (2015). Mesenchymal stem cells: rising concerns over their application in treatment of type one diabetes mellitus. Journal of Diabetes Research, 2015.

He, Y., Zhang, D., Zeng, Y., Ma, J., Wang, J., Guo, H., Zhang, J., Wang, M., Zhang, W., & Gong, N. (2018). Bone marrow-derived mesenchymal stem cells protect islet grafts against endoplasmic reticulum stress-induced apoptosis during the early stage after transplantation. Stem Cells, 36(7), 1045–1061.

Hess, D., Li, L., Martin, M., Sakano, S., Hill, D., Strutt, B., Thyssen, S., Gray, D. A., & Bhatia, M. (2003). Bone marrow–derived stem cells initiate pancreatic regeneration. Nature Biotechnology, 21(7), 763–770.

Ho, J. H., Tseng, T.-C., Ma, W.-H., Ong, W.-K., Chen, Y.-F., Chen, M.-H., Lin, M.-W., Hong, C.-Y., & Lee, O. K. (2012). Multiple intravenous transplantations of mesenchymal stem cells effectively restore long-term blood glucose homeostasis by hepatic engraftment and ?-cell differentiation in streptozocin-induced diabetic mice. Cell Transplantation, 21(5), 997–1009.

Hu, J., Li, C., Wang, L., Zhang, X., Zhang, M., Gao, H., Yu, X., Wang, F., Zhao, W., & Yan, S. (2012). Long term effects of the implantation of autologous bone marrow mononuclear cells for type 2 diabetes mellitus. Endocrine Journal, 59(11), 1031–1039.

Huang, Q., Huang, Y., & Liu, J. (2021). Mesenchymal stem cells: an excellent candidate for the treatment of diabetes mellitus. International Journal of Endocrinology, 2021.

Inzucchi, S. E. (2002). Oral antihyperglycemic therapy for type 2 diabetes: scientific review. Jama, 287(3), 360–372.

Jadalannagari, S., & Aljitawi, O. S. (2015). Ectodermal differentiation of wharton’s jelly mesenchymal stem cells for tissue engineering and regenerative medicine applications. Tissue Engineering Part B: Reviews, 21(3), 314–322.

Jiang, R., Han, Z., Zhuo, G., Qu, X., Li, X., Wang, X., Shao, Y., Yang, S., & Han, Z. C. (2011). Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study. Frontiers of Medicine, 5(1), 94–100.

Jiang, W., Tan, Y., Cai, M., Zhao, T., Mao, F., Zhang, X., Xu, W., Yan, Z., Qian, H., & Yan, Y. (2018). Human umbilical cord MSC-derived exosomes suppress the development of CCl 4-induced liver injury through antioxidant effect. Stem Cells International, 2018.

Kadam, S. S., Sudhakar, M., Nair, P. D., & Bhonde, R. R. (2010). Reversal of experimental diabetes in mice by transplantation of neo-islets generated from human amnion-derived mesenchymal stromal cells using immuno-isolatory macrocapsules. Cytotherapy, 12(8), 982–991.

Kasoju, N., Wang, H., Zhang, B., George, J., Gao, S., Triffitt, J. T., Cui, Z., & Ye, H. (2017). Transcriptomics of human multipotent mesenchymal stromal cells: retrospective analysis and future prospects. Biotechnology Advances, 35(4), 407–418.

Kim, H.-J., Li, Q., Song, W.-J., Yang, H.-M., Kim, S.-Y., Park, S.-C., Ahn, J.-O., & Youn, H.-Y. (2018). Fibroblast growth factor-1 as a mediator of paracrine effects of canine adipose tissue-derived mesenchymal stem cells on in vitro-induced insulin resistance models. BMC Veterinary Research, 14, 1–10.

Kim, H. Y., Hwang, J.-I., Moon, M. J., & Seong, J. Y. (2014). A novel long-acting glucagon-like peptide-1 agonist with improved efficacy in insulin secretion and ?-cell growth. Endocrinology and Metabolism, 29(3), 320–327.

Kim, J., Park, S., Kang, H. M., Ahn, C. W., Kwon, H. C., Song, J. H., Lee, Y. J., Lee, K. H., Yang, H., & Baek, S. Y. (2012). Human insulin secreted from insulinogenic xenograft restores normoglycemia in type 1 diabetic mice without immunosuppression. Cell Transplantation, 21(10), 2131–2147.

Kim, N., & Cho, S.-G. (2013). Clinical applications of mesenchymal stem cells. The Korean Journal of Internal Medicine, 28(4), 387.

Konari, N., Nagaishi, K., Kikuchi, S., & Fujimiya, M. (2019). Mitochondria transfer from mesenchymal stem cells structurally and functionally repairs renal proximal tubular epithelial cells in diabetic nephropathy in vivo. Scientific Reports, 9(1), 5184.

Kong, D., Zhuang, X., Wang, D., Qu, H., Jiang, Y., Li, X., Wu, W., Xiao, J., Liu, X., & Liu, J. (2014). Umbilical cord mesenchymal stem cell transfusion ameliorated hyperglycemia in patients with type 2 diabetes mellitus. Clinical Laboratory, 60(12), 1969–1976.

Kuriyan, A. E., Albini, T. A., Townsend, J. H., Rodriguez, M., Pandya, H. K., Leonard, R. E., Parrott, M. B., Rosenfeld, P. J., Flynn Jr, H. W., & Goldberg, J. L. (2017). Vision loss after intravitreal injection of autologous “stem cells” for AMD. New England Journal of Medicine, 376(11), 1047–1053.

Lee, C.-W., Hsiao, W.-T., & Lee, O. K.-S. (2017). Mesenchymal stromal cell-based therapies reduce obesity and metabolic syndromes induced by a high-fat diet. Translational Research, 182, 61–74.

Lee, R. H., Seo, M. J., Reger, R. L., Spees, J. L., Pulin, A. A., Olson, S. D., & Prockop, D. J. (2006). Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proceedings of the National Academy of Sciences, 103(46), 17438–17443.

Leibacher, J., Dauber, K., Ehser, S., Brixner, V., Kollar, K., Vogel, A., Spohn, G., Schäfer, R., Seifried, E., & Henschler, R. (2017). Human mesenchymal stromal cells undergo apoptosis and fragmentation after intravenous application in immune-competent mice. Cytotherapy, 19(1), 61–74.

Li, Y., Wang, F., Liang, H., Tang, D., Huang, M., Zhao, J., Yang, X., Liu, Y., Shu, L., & Wang, J. (2021). Efficacy of mesenchymal stem cell transplantation therapy for type 1 and type 2 diabetes mellitus: a meta-analysis. Stem Cell Research & Therapy, 12(1), 273.

Liao, L., Shi, B., Chang, H., Su, X., Zhang, L., Bi, C., Shuai, Y., Du, X., Deng, Z., & Jin, Y. (2017). Heparin improves BMSC cell therapy: anticoagulant treatment by heparin improves the safety and therapeutic effect of bone marrow-derived mesenchymal stem cell cytotherapy. Theranostics, 7(1), 106.

Liu, X., Zheng, P., Wang, X., Dai, G., Cheng, H., Zhang, Z., Hua, R., Niu, X., Shi, J., & An, Y. (2014). A preliminary evaluation of efficacy and safety of Wharton’s jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus. Stem Cell Research & Therapy, 5(2), 1–9.

Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., & Ahn, S. Y. (2012). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet, 380(9859), 2095–2128.

Ma, S., Xie, N., Li, W., Yuan, B., Shi, Y., & Wang, Y. (2014). Immunobiology of mesenchymal stem cells. Cell Death & Differentiation, 21(2), 216–225.

Mäkelä, T., Takalo, R., Arvola, O., Haapanen, H., Yannopoulos, F., Blanco, R., Ahvenjärvi, L., Kiviluoma, K., Kerkelä, E., & Nystedt, J. (2015). Safety and biodistribution study of bone marrow–derived mesenchymal stromal cells and mononuclear cells and the impact of the administration route in an intact porcine model. Cytotherapy, 17(4), 392–402.

Maksimova, N. V, Michenko, A. V, Krasilnikova, O. A., Klabukov, I. D., Gadaev, I. Y., Krasheninnikov, M. E., Belkov, P. A., & Lyundup, A. V. (2022). Mesenchymal stromal cell therapy alone does not lead to complete restoration of skin parameters in diabetic foot patients within a 3-year follow-up period. BioImpacts: BI, 12(1), 51.

Mathur, A., Taurin, S., & Alshammary, S. (2023). The Safety and Efficacy of Mesenchymal Stem Cells in the Treatment of Type 2 Diabetes-A Literature Review. Diabetes, Metabolic Syndrome and Obesity, 769–777.

Nagaishi, K., Ataka, K., Echizen, E., Arimura, Y., & Fujimiya, M. (2014). Mesenchymal stem cell therapy ameliorates diabetic hepatocyte damage in mice by inhibiting infiltration of bone marrow–derived cells. Hepatology, 59(5), 1816–1829.

Packer, M. (2018). The Alchemist’s nightmare: Might mesenchymal stem cells that are recruited to repair the injured heart be transformed into fibroblasts rather than cardiomyocytes? Circulation, 137(19), 2068–2073.

Park, K.-S., Kim, Y.-S., Kim, J.-H., Choi, B., Kim, S.-H., Tan, A. H.-K., Lee, M.-S., Lee, M.-K., Kwon, C.-H., & Joh, J.-W. (2010). Trophic molecules derived from human mesenchymal stem cells enhance survival, function, and angiogenesis of isolated islets after transplantation. Transplantation, 89(5), 509–517.

Planat-Benard, V., Varin, A., & Casteilla, L. (2021). MSCs and inflammatory cells crosstalk in regenerative medicine: concerted actions for optimized resolution driven by energy metabolism. Frontiers in Immunology, 12, 626755.

Rackham, C. L., Hubber, E. L., Czajka, A., Malik, A. N., King, A. J. F., & Jones, P. M. (2020). Optimizing beta cell function through mesenchymal stromal cell-mediated mitochondria transfer. Stem Cells, 38(4), 574–584.

Rahim, F., Arjmand, B., Shirbandi, K., Payab, M., & Larijani, B. (2018). Stem cell therapy for patients with diabetes: a systematic review and meta-analysis of metabolomics-based risks and benefits. Stem Cell Investigation, 5.

Ranjbaran, H., Mohammadi Jobani, B., Amirfakhrian, E., & Alizadeh?Navaei, R. (2021). Efficacy of mesenchymal stem cell therapy on glucose levels in type 2 diabetes mellitus: A systematic review and meta?analysis. Journal of Diabetes Investigation, 12(5), 803–810.

Raz, I., Riddle, M. C., Rosenstock, J., Buse, J. B., Inzucchi, S. E., Home, P. D., Del Prato, S., Ferrannini, E., Chan, J. C. N., & Leiter, L. A. (2013). Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors’ Expert Forum. Am Diabetes Assoc.

Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., & Ogurtsova, K. (2019). Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes Research and Clinical Practice, 157, 107843.

Sasaki, S., Miyatsuka, T., Matsuoka, T., Takahara, M., Yamamoto, Y., Yasuda, T., Kaneto, H., Fujitani, Y., German, M. S., & Akiyama, H. (2015). Activation of GLP-1 and gastrin signalling induces in vivo reprogramming of pancreatic exocrine cells into beta cells in mice. Diabetologia, 58, 2582–2591.

Schrepfer, S., Deuse, T., Reichenspurner, H., Fischbein, M. P., Robbins, R. C., & Pelletier, M. P. (2007). Stem cell transplantation: the lung barrier. Transplantation Proceedings, 39(2), 573–576.

Seyedi, F., Farsinejad, A., Nematollahi-Mahani, S. A., Eslaminejad, T., & Nematollahi-Mahani, S. N. (2016). Suspension culture alters insulin secretion in induced human umbilical cord matrix-derived mesenchymal cells. Cell Journal (Yakhteh), 18(1), 52.

Shrestha, M., Nguyen, T. T., Park, J., Choi, J. U., Yook, S., & Jeong, J.-H. (2021). Immunomodulation effect of mesenchymal stem cells in islet transplantation. Biomedicine & Pharmacotherapy, 142, 112042.

Shulman, G. I., Rothman, D. L., Jue, T., Stein, P., DeFronzo, R. A., & Shulman, R. G. (1990). Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. New England Journal of Medicine, 322(4), 223–228.

Si, Y.-L., Zhao, Y.-L., Hao, H.-J., Fu, X.-B., & Han, W.-D. (2011). MSCs: biological characteristics, clinical applications and their outstanding concerns. Ageing Research Reviews, 10(1), 93–103.

Si, Y., Zhao, Y., Hao, H., Liu, J., Guo, Y., Mu, Y., Shen, J., Cheng, Y., Fu, X., & Han, W. (2012). Infusion of mesenchymal stem cells ameliorates hyperglycemia in type 2 diabetic rats: identification of a novel role in improving insulin sensitivity. Diabetes, 61(6), 1616–1625.

Singer, N. G., & Caplan, A. I. (2011). Mesenchymal stem cells: mechanisms of inflammation. Annual Review of Pathology: Mechanisms of Disease, 6, 457–478.

Sivanathan, K. N., Rojas-Canales, D. M., Hope, C. M., Krishnan, R., Carroll, R. P., Gronthos, S., Grey, S. T., & Coates, P. T. (2015). Interleukin-17A-induced human mesenchymal stem cells are superior modulators of immunological function. Stem Cells, 33(9), 2850–2863.

Skyler, J. S., Fonseca, V. A., Segal, K. R., & Rosenstock, J. (2015). Allogeneic mesenchymal precursor cells in type 2 diabetes: a randomized, placebo-controlled, dose-escalation safety and tolerability pilot study. Diabetes Care, 38(9), 1742–1749.

Sood, V., Mittal, B. R., Bhansali, A., Singh, B., Khandelwal, N., Marwaha, N., & Jain, A. (2015). Biodistribution of 18F-FDG-labeled autologous bone marrow–derived stem cells in patients with type 2 diabetes mellitus: exploring targeted and intravenous routes of delivery. Clinical Nuclear Medicine, 40(9), 697–700.

Su, T., Xiao, Y., Xiao, Y. E., Guo, Q. I., Li, C., Huang, Y., Deng, Q., Wen, J., Zhou, F., & Luo, X.-H. (2019). Bone marrow mesenchymal stem cells-derived exosomal MiR-29b-3p regulates aging-associated insulin resistance. ACS Nano, 13(2), 2450–2462.

Sun, X., Hao, H., Han, Q., Song, X., Liu, J., Dong, L., Han, W., & Mu, Y. (2017). Human umbilical cord-derived mesenchymal stem cells ameliorate insulin resistance by suppressing NLRP3 inflammasome-mediated inflammation in type 2 diabetes rats. Stem Cell Research & Therapy, 8, 1–14.

Thom, S. R., Bhopale, V. M., Velazquez, O. C., Goldstein, L. J., Thom, L. H., & Buerk, D. G. (2006). Stem cell mobilization by hyperbaric oxygen. American Journal of Physiology-Heart and Circulatory Physiology.

Timmers, L., Lim, S. K., Arslan, F., Armstrong, J. S., Hoefer, I. E., Doevendans, P. A., Piek, J. J., El Oakley, R. M., Choo, A., & Lee, C. N. (2008). Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Research, 1(2), 129–137.

Vining, K. H., & Mooney, D. J. (2017). Mechanical forces direct stem cell behaviour in development and regeneration. Nature Reviews Molecular Cell Biology, 18(12), 728–742.

Volarevic, V., Arsenijevic, N., Lukic, M. L., & Stojkovic, M. (2011). Concise review: mesenchymal stem cell treatment of the complications of diabetes mellitus. Stem Cells, 29(1), 5–10.

Wang, L., Liu, T., Liang, R., Wang, G., Liu, Y., Zou, J., Liu, N., Zhang, B., Liu, Y., & Ding, X. (2020). Mesenchymal stem cells ameliorate ? cell dysfunction of human type 2 diabetic islets by reversing ? cell dedifferentiation. EBioMedicine, 51.

Wang, M., Song, L., Strange, C., Dong, X., & Wang, H. (2018). Therapeutic effects of adipose stem cells from diabetic mice for the treatment of type 2 diabetes. Molecular Therapy, 26(8), 1921–1930.

Wei, Y., Rector, R. S., Thyfault, J. P., & Ibdah, J. A. (2008). Nonalcoholic fatty liver disease and mitochondrial dysfunction. World Journal of Gastroenterology: WJG, 14(2), 193.

Wu, Z., Cai, J., Chen, J., Huang, L., Wu, W., Luo, F., Wu, C., Liao, L., & Tan, J. (2014). Autologous bone marrow mononuclear cell infusion and hyperbaric oxygen therapy in type 2 diabetes mellitus: an open-label, randomized controlled clinical trial. Cytotherapy, 16(2), 258–265.

Xie, M., Hao, H. J., Cheng, Y. U., Xie, Z. Y., Yin, Y. Q., Zhang, Q., Gao, J. Q., Liu, H. Y., Mu, Y. M., & Han, W. D. (2017). Adipose-derived mesenchymal stem cells ameliorate hyperglycemia through regulating hepatic glucose metabolism in type 2 diabetic rats. Biochemical and Biophysical Research Communications, 483(1), 435–441.

Xie, Z., Hao, H., Tong, C., Cheng, Y., Liu, J., Pang, Y., Si, Y., Guo, Y., Zang, L., & Mu, Y. (2016). Human umbilical cord-derived mesenchymal stem cells elicit macrophages into an anti-inflammatory phenotype to alleviate insulin resistance in type 2 diabetic rats. Stem Cells, 34(3), 627–639.

Yin, Y., Hao, H., Cheng, Y., Zang, L., Liu, J., Gao, J., Xue, J., Xie, Z., Zhang, Q., & Han, W. (2018). Human umbilical cord-derived mesenchymal stem cells direct macrophage polarization to alleviate pancreatic islets dysfunction in type 2 diabetic mice. Cell Death & Disease, 9(7), 760.

Yu, J. M., Jun, E. S., Bae, Y. C., & Jung, J. S. (2008). Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo. Stem Cells and Development, 17(3), 463–474.

Yuan, Y., Yuan, L., Li, L., Liu, F., Liu, J., Chen, Y., Cheng, J., & Lu, Y. (2021). Mitochondrial transfer from mesenchymal stem cells to macrophages restricts inflammation and alleviates kidney injury in diabetic nephropathy mice via PGC-1? activation. Stem Cells, 39(7), 913–928.

Zang, L., Hao, H., Liu, J., Li, Y., Han, W., & Mu, Y. (2017). Mesenchymal stem cell therapy in type 2 diabetes mellitus. Diabetology & Metabolic Syndrome, 9, 1–11.

Zhang, Yi, Cai, W., Huang, Q., Gu, Y., Shi, Y., Huang, J., Zhao, F., Liu, Q., Wei, X., & Jin, M. (2014). Mesenchymal stem cells alleviate bacteria?induced liver injury in mice by inducing regulatory dendritic cells. Hepatology, 59(2), 671–682.

Zhang, Yuanyuan, Gao, S., Liang, K., Wu, Z., Yan, X., Liu, W., Li, J., Wu, B., & Du, Y. (2021). Exendin-4 gene modification and microscaffold encapsulation promote self-persistence and antidiabetic activity of MSCs. Science Advances, 7(27), eabi4379.

Zhao, K., Hao, H., Liu, J., Tong, C., Cheng, Y., Xie, Z., Zang, L., Mu, Y., & Han, W. (2015). Bone marrow-derived mesenchymal stem cells ameliorate chronic high glucose-induced ?-cell injury through modulation of autophagy. Cell Death & Disease, 6(9), e1885–e1885.

Zhao, Y., Jiang, Z., Zhao, T., Ye, M., Hu, C., Zhou, H., Yin, Z., Chen, Y., Zhang, Y., & Wang, S. (2013). Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase I/II clinical trial. BMC Medicine, 11, 1–13.

Zhou, Y., Hu, Q., Chen, F., Zhang, J., Guo, J., Wang, H., Gu, J., Ma, L., & Ho, G. (2015). Human umbilical cord matrix-derived stem cells exert trophic effects on ?-cell survival in diabetic rats and isolated islets. Disease Models & Mechanisms, 8(12), 1625–1633.

Therapeutic of Mesenchymal Stem Cells in Diabetes

Authors

DOI:

Keywords:

Abstract

References

Downloads

Published

How to Cite

Issue

Section

License

Most read articles by the same author(s)